FT
Schedule 13G filing
Franklin Templeton Inc disclosed a 5.2% stake in CTNM
Franklin Templeton Inc reported owning 5.2% of Contineum Therapeutics, Inc. (CTNM) (1,704,550 shares) in a Schedule 13G filed Oct 28, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 28, 2026
- Source
- Schedule 13G
More CTNM insider and Congress trades
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.